A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, open, dose-escalation study to observe the safety and efficacy
of different doses of CAR-GPRC5D in patients with R/R MM or plasma cell leukemia.